TILs variations, proliferative response and PEPI scores in patients with luminal breast cancer receiving neoadjuvant letrozole-palbociclib or chemotherapy: An extended analysis of the NEOPAL trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreTILs variations, proliferative response and PEPI scores in patients with luminal breast cancer receiving neoadjuvant letrozole-palbociclib or chemotherapy: An extended analysis of the NEOPAL trial
Type de publicationJournal Article
Year of Publication2019
AuteursVincent-Salomon A., Mathieu M-C, Bataillon G., Arnould L., Verriele V., Ghnassia J-P, Haudebourg J., Penault-Llorca F., Lefebvre C., Maran-Gonzalez A., Guinebretiere J-M, Duprez R., Berghian A., Blanc-Fournier C., Cales V., Galant C., Delree P., Lemonnier J., Delaloge S., Cottu P.H
JournalCANCER RESEARCH
Volume79
Date PublishedFEB
Type of ArticleMeeting Abstract
ISSN0008-5472
DOI10.1158/1538-7445.SABCS18-P4-15-02